Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.
Identifieur interne : 000375 ( Main/Exploration ); précédent : 000374; suivant : 000376Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.
Auteurs : Camelia Savulescu [Espagne] ; Silvia Jiménez-Jorge ; Salvador De Mateo ; Francisco Pozo ; Inmaculada Casas ; Pilar Pérez Bre A ; Antonia Galmés ; Juana M. Vanrell ; Carolina Rodriguez ; Tomas Vega ; Ana Martinez ; Nuria Torner ; Julián M. Ramos ; Maria C. Serrano ; Jesús Castilla ; Manuel García Cenoz ; Jone M. Altzibar ; Jose M. Arteagoitia ; Carmen Qui Ones ; Milagros Perucha ; Amparo LarrauriSource :
- BMC public health [ 1471-2458 ] ; 2011.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H1N1 du virus de la grippe A (isolement et purification), Surveillance de la population (MeSH), Vaccins antigrippaux (usage thérapeutique), Études cas-témoins (MeSH).
- MESH :
- immunologie : Sous-type H1N1 du virus de la grippe A.
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- prévention et contrôle : Grippe humaine.
- usage thérapeutique : Vaccins antigrippaux.
- virologie : Grippe humaine.
- épidémiologie : Espagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Surveillance de la population, Études cas-témoins.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Case-Control Studies (MeSH), Female (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Outcome Assessment, Health Care (MeSH), Population Surveillance (MeSH), Spain (epidemiology), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Influenza Vaccines.
- geographic , epidemiology : Spain.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Case-Control Studies, Female, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Population Surveillance, Young Adult.
Abstract
BACKGROUND
Physicians of the Spanish Influenza Sentinel Surveillance System report and systematically swab patients attended to their practices for influenza-like illness (ILI). Within the surveillance system, some Spanish regions also participated in an observational study aiming at estimating influenza vaccine effectiveness (cycEVA study). During the season 2009-2010, we estimated pandemic influenza vaccine effectiveness using both the influenza surveillance data and the cycEVA study.
METHODS
We conducted two case-control studies using the test-negative design, between weeks 48/2009 and 8/2010 of the pandemic season. The surveillance-based study included all swabbed patients in the sentinel surveillance system. The cycEVA study included swabbed patients from seven Spanish regions. Cases were laboratory-confirmed pandemic influenza A(H1N1)2009. Controls were ILI patients testing negative for any type of influenza. Variables collected in both studies included demographic data, vaccination status, laboratory results, chronic conditions, and pregnancy. Additionally, cycEVA questionnaire collected data on previous influenza vaccination, smoking, functional status, hospitalisations, visits to the general practitioners, and obesity. We used logistic regression to calculate adjusted odds ratios (OR), computing pandemic influenza vaccine effectiveness as (1-OR)*100.
RESULTS
We included 331 cases and 995 controls in the surveillance-based study and 85 cases and 351 controls in the cycEVA study. We detected nine (2.7%) and two (2.4%) vaccine failures in the surveillance-based and cycEVA studies, respectively. Adjusting for variables collected in surveillance database and swabbing month, pandemic influenza vaccine effectiveness was 62% (95% confidence interval (CI): -5; 87). The cycEVA vaccine effectiveness was 64% (95%CI: -225; 96) when adjusting for common variables with the surveillance system and 75% (95%CI: -293; 98) adjusting for all variables collected.
CONCLUSION
Point estimates of the pandemic influenza vaccine effectiveness suggested a protective effect of the pandemic vaccine against laboratory-confirmed influenza A(H1N1)2009 in the season 2009-2010. Both studies were limited by the low vaccine coverage and the late start of the vaccination campaign. Routine influenza surveillance provides reliable estimates and could be used for influenza vaccine effectiveness studies in future seasons taken into account the surveillance system limitations.
DOI: 10.1186/1471-2458-11-899
PubMed: 22129083
PubMed Central: PMC3262832
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.</title><author><name sortKey="Savulescu, Camelia" sort="Savulescu, Camelia" uniqKey="Savulescu C" first="Camelia" last="Savulescu">Camelia Savulescu</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no,5, 28029 Madrid, Spain. csavulescu@isciii.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no,5, 28029 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name></author><author><name sortKey="De Mateo, Salvador" sort="De Mateo, Salvador" uniqKey="De Mateo S" first="Salvador" last="De Mateo">Salvador De Mateo</name></author><author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name></author><author><name sortKey="Casas, Inmaculada" sort="Casas, Inmaculada" uniqKey="Casas I" first="Inmaculada" last="Casas">Inmaculada Casas</name></author><author><name sortKey="Bre A, Pilar Perez" sort="Bre A, Pilar Perez" uniqKey="Bre A P" first="Pilar Pérez" last="Bre A">Pilar Pérez Bre A</name></author><author><name sortKey="Galmes, Antonia" sort="Galmes, Antonia" uniqKey="Galmes A" first="Antonia" last="Galmés">Antonia Galmés</name></author><author><name sortKey="Vanrell, Juana M" sort="Vanrell, Juana M" uniqKey="Vanrell J" first="Juana M" last="Vanrell">Juana M. Vanrell</name></author><author><name sortKey="Rodriguez, Carolina" sort="Rodriguez, Carolina" uniqKey="Rodriguez C" first="Carolina" last="Rodriguez">Carolina Rodriguez</name></author><author><name sortKey="Vega, Tomas" sort="Vega, Tomas" uniqKey="Vega T" first="Tomas" last="Vega">Tomas Vega</name></author><author><name sortKey="Martinez, Ana" sort="Martinez, Ana" uniqKey="Martinez A" first="Ana" last="Martinez">Ana Martinez</name></author><author><name sortKey="Torner, Nuria" sort="Torner, Nuria" uniqKey="Torner N" first="Nuria" last="Torner">Nuria Torner</name></author><author><name sortKey="Ramos, Julian M" sort="Ramos, Julian M" uniqKey="Ramos J" first="Julián M" last="Ramos">Julián M. Ramos</name></author><author><name sortKey="Serrano, Maria C" sort="Serrano, Maria C" uniqKey="Serrano M" first="Maria C" last="Serrano">Maria C. Serrano</name></author><author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name></author><author><name sortKey="Cenoz, Manuel Garcia" sort="Cenoz, Manuel Garcia" uniqKey="Cenoz M" first="Manuel García" last="Cenoz">Manuel García Cenoz</name></author><author><name sortKey="Altzibar, Jone M" sort="Altzibar, Jone M" uniqKey="Altzibar J" first="Jone M" last="Altzibar">Jone M. Altzibar</name></author><author><name sortKey="Arteagoitia, Jose M" sort="Arteagoitia, Jose M" uniqKey="Arteagoitia J" first="Jose M" last="Arteagoitia">Jose M. Arteagoitia</name></author><author><name sortKey="Qui Ones, Carmen" sort="Qui Ones, Carmen" uniqKey="Qui Ones C" first="Carmen" last="Qui Ones">Carmen Qui Ones</name></author><author><name sortKey="Perucha, Milagros" sort="Perucha, Milagros" uniqKey="Perucha M" first="Milagros" last="Perucha">Milagros Perucha</name></author><author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22129083</idno><idno type="pmid">22129083</idno><idno type="doi">10.1186/1471-2458-11-899</idno><idno type="pmc">PMC3262832</idno><idno type="wicri:Area/Main/Corpus">00334</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00334</idno><idno type="wicri:Area/Main/Curation">000334</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000334</idno><idno type="wicri:Area/Main/Exploration">000334</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.</title><author><name sortKey="Savulescu, Camelia" sort="Savulescu, Camelia" uniqKey="Savulescu C" first="Camelia" last="Savulescu">Camelia Savulescu</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no,5, 28029 Madrid, Spain. csavulescu@isciii.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no,5, 28029 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name></author><author><name sortKey="De Mateo, Salvador" sort="De Mateo, Salvador" uniqKey="De Mateo S" first="Salvador" last="De Mateo">Salvador De Mateo</name></author><author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name></author><author><name sortKey="Casas, Inmaculada" sort="Casas, Inmaculada" uniqKey="Casas I" first="Inmaculada" last="Casas">Inmaculada Casas</name></author><author><name sortKey="Bre A, Pilar Perez" sort="Bre A, Pilar Perez" uniqKey="Bre A P" first="Pilar Pérez" last="Bre A">Pilar Pérez Bre A</name></author><author><name sortKey="Galmes, Antonia" sort="Galmes, Antonia" uniqKey="Galmes A" first="Antonia" last="Galmés">Antonia Galmés</name></author><author><name sortKey="Vanrell, Juana M" sort="Vanrell, Juana M" uniqKey="Vanrell J" first="Juana M" last="Vanrell">Juana M. Vanrell</name></author><author><name sortKey="Rodriguez, Carolina" sort="Rodriguez, Carolina" uniqKey="Rodriguez C" first="Carolina" last="Rodriguez">Carolina Rodriguez</name></author><author><name sortKey="Vega, Tomas" sort="Vega, Tomas" uniqKey="Vega T" first="Tomas" last="Vega">Tomas Vega</name></author><author><name sortKey="Martinez, Ana" sort="Martinez, Ana" uniqKey="Martinez A" first="Ana" last="Martinez">Ana Martinez</name></author><author><name sortKey="Torner, Nuria" sort="Torner, Nuria" uniqKey="Torner N" first="Nuria" last="Torner">Nuria Torner</name></author><author><name sortKey="Ramos, Julian M" sort="Ramos, Julian M" uniqKey="Ramos J" first="Julián M" last="Ramos">Julián M. Ramos</name></author><author><name sortKey="Serrano, Maria C" sort="Serrano, Maria C" uniqKey="Serrano M" first="Maria C" last="Serrano">Maria C. Serrano</name></author><author><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name></author><author><name sortKey="Cenoz, Manuel Garcia" sort="Cenoz, Manuel Garcia" uniqKey="Cenoz M" first="Manuel García" last="Cenoz">Manuel García Cenoz</name></author><author><name sortKey="Altzibar, Jone M" sort="Altzibar, Jone M" uniqKey="Altzibar J" first="Jone M" last="Altzibar">Jone M. Altzibar</name></author><author><name sortKey="Arteagoitia, Jose M" sort="Arteagoitia, Jose M" uniqKey="Arteagoitia J" first="Jose M" last="Arteagoitia">Jose M. Arteagoitia</name></author><author><name sortKey="Qui Ones, Carmen" sort="Qui Ones, Carmen" uniqKey="Qui Ones C" first="Carmen" last="Qui Ones">Carmen Qui Ones</name></author><author><name sortKey="Perucha, Milagros" sort="Perucha, Milagros" uniqKey="Perucha M" first="Milagros" last="Perucha">Milagros Perucha</name></author><author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name></author></analytic><series><title level="j">BMC public health</title><idno type="eISSN">1471-2458</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Outcome Assessment, Health Care (MeSH)</term><term>Population Surveillance (MeSH)</term><term>Spain (epidemiology)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Surveillance de la population (MeSH)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment, Health Care</term><term>Population Surveillance</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Surveillance de la population</term><term>Études cas-témoins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Physicians of the Spanish Influenza Sentinel Surveillance System report and systematically swab patients attended to their practices for influenza-like illness (ILI). Within the surveillance system, some Spanish regions also participated in an observational study aiming at estimating influenza vaccine effectiveness (cycEVA study). During the season 2009-2010, we estimated pandemic influenza vaccine effectiveness using both the influenza surveillance data and the cycEVA study.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We conducted two case-control studies using the test-negative design, between weeks 48/2009 and 8/2010 of the pandemic season. The surveillance-based study included all swabbed patients in the sentinel surveillance system. The cycEVA study included swabbed patients from seven Spanish regions. Cases were laboratory-confirmed pandemic influenza A(H1N1)2009. Controls were ILI patients testing negative for any type of influenza. Variables collected in both studies included demographic data, vaccination status, laboratory results, chronic conditions, and pregnancy. Additionally, cycEVA questionnaire collected data on previous influenza vaccination, smoking, functional status, hospitalisations, visits to the general practitioners, and obesity. We used logistic regression to calculate adjusted odds ratios (OR), computing pandemic influenza vaccine effectiveness as (1-OR)*100.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We included 331 cases and 995 controls in the surveillance-based study and 85 cases and 351 controls in the cycEVA study. We detected nine (2.7%) and two (2.4%) vaccine failures in the surveillance-based and cycEVA studies, respectively. Adjusting for variables collected in surveillance database and swabbing month, pandemic influenza vaccine effectiveness was 62% (95% confidence interval (CI): -5; 87). The cycEVA vaccine effectiveness was 64% (95%CI: -225; 96) when adjusting for common variables with the surveillance system and 75% (95%CI: -293; 98) adjusting for all variables collected.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Point estimates of the pandemic influenza vaccine effectiveness suggested a protective effect of the pandemic vaccine against laboratory-confirmed influenza A(H1N1)2009 in the season 2009-2010. Both studies were limited by the low vaccine coverage and the late start of the vaccination campaign. Routine influenza surveillance provides reliable estimates and could be used for influenza vaccine effectiveness studies in future seasons taken into account the surveillance system limitations.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22129083</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2011</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.</ArticleTitle><Pagination><MedlinePgn>899</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2458-11-899</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Physicians of the Spanish Influenza Sentinel Surveillance System report and systematically swab patients attended to their practices for influenza-like illness (ILI). Within the surveillance system, some Spanish regions also participated in an observational study aiming at estimating influenza vaccine effectiveness (cycEVA study). During the season 2009-2010, we estimated pandemic influenza vaccine effectiveness using both the influenza surveillance data and the cycEVA study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted two case-control studies using the test-negative design, between weeks 48/2009 and 8/2010 of the pandemic season. The surveillance-based study included all swabbed patients in the sentinel surveillance system. The cycEVA study included swabbed patients from seven Spanish regions. Cases were laboratory-confirmed pandemic influenza A(H1N1)2009. Controls were ILI patients testing negative for any type of influenza. Variables collected in both studies included demographic data, vaccination status, laboratory results, chronic conditions, and pregnancy. Additionally, cycEVA questionnaire collected data on previous influenza vaccination, smoking, functional status, hospitalisations, visits to the general practitioners, and obesity. We used logistic regression to calculate adjusted odds ratios (OR), computing pandemic influenza vaccine effectiveness as (1-OR)*100.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 331 cases and 995 controls in the surveillance-based study and 85 cases and 351 controls in the cycEVA study. We detected nine (2.7%) and two (2.4%) vaccine failures in the surveillance-based and cycEVA studies, respectively. Adjusting for variables collected in surveillance database and swabbing month, pandemic influenza vaccine effectiveness was 62% (95% confidence interval (CI): -5; 87). The cycEVA vaccine effectiveness was 64% (95%CI: -225; 96) when adjusting for common variables with the surveillance system and 75% (95%CI: -293; 98) adjusting for all variables collected.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Point estimates of the pandemic influenza vaccine effectiveness suggested a protective effect of the pandemic vaccine against laboratory-confirmed influenza A(H1N1)2009 in the season 2009-2010. Both studies were limited by the low vaccine coverage and the late start of the vaccination campaign. Routine influenza surveillance provides reliable estimates and could be used for influenza vaccine effectiveness studies in future seasons taken into account the surveillance system limitations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savulescu</LastName><ForeName>Camelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no,5, 28029 Madrid, Spain. csavulescu@isciii.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiménez-Jorge</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>de Mateo</LastName><ForeName>Salvador</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pozo</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Breña</LastName><ForeName>Pilar Pérez</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Galmés</LastName><ForeName>Antonia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vanrell</LastName><ForeName>Juana M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vega</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Torner</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Julián M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Castilla</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cenoz</LastName><ForeName>Manuel García</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Altzibar</LastName><ForeName>Jone M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Arteagoitia</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Quiñones</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Perucha</LastName><ForeName>Milagros</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Larrauri</LastName><ForeName>Amparo</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="Y">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22129083</ArticleId><ArticleId IdType="pii">1471-2458-11-899</ArticleId><ArticleId IdType="doi">10.1186/1471-2458-11-899</ArticleId><ArticleId IdType="pmc">PMC3262832</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Methods Inf Med. 1998 Sep;37(3):266-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9787627</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2011 Jan;8(1):e1000388</Citation><ArticleIdList><ArticleId IdType="pubmed">21379316</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2007 May;12(5):E070531.3</Citation><ArticleIdList><ArticleId IdType="pubmed">17868585</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2007 May;12(5):E5-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17991396</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2008 Oct 23;13(43). pii: 19015</Citation><ArticleIdList><ArticleId IdType="pubmed">18947520</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):168-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19086914</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):159-67</Citation><ArticleIdList><ArticleId IdType="pubmed">19086915</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(3):e5079</Citation><ArticleIdList><ArticleId IdType="pubmed">19333374</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2009 May 14;14(19). pii: 19209</Citation><ArticleIdList><ArticleId IdType="pubmed">19442404</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Apr 1;28(16):2903-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20153351</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010 May 6;15(18). pii: 19561</Citation><ArticleIdList><ArticleId IdType="pubmed">20460094</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2010 Jul;14(34):313-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20630126</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Nov 3;28(47):7460-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20875486</ArticleId></ArticleIdList></Reference><Reference><Citation>J Epidemiol Community Health. 2010 Dec;64(12):1062-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19910645</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2011;16(2). pii: 19763</Citation><ArticleIdList><ArticleId IdType="pubmed">21251487</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011;342:c7297</Citation><ArticleIdList><ArticleId IdType="pubmed">21292718</ArticleId></ArticleIdList></Reference><Reference><Citation>Gac Sanit. 2011 Jan-Feb;25(1):23-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21334788</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Apr 12;25(15):2842-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17081662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region></list><tree><noCountry><name sortKey="Altzibar, Jone M" sort="Altzibar, Jone M" uniqKey="Altzibar J" first="Jone M" last="Altzibar">Jone M. Altzibar</name><name sortKey="Arteagoitia, Jose M" sort="Arteagoitia, Jose M" uniqKey="Arteagoitia J" first="Jose M" last="Arteagoitia">Jose M. Arteagoitia</name><name sortKey="Bre A, Pilar Perez" sort="Bre A, Pilar Perez" uniqKey="Bre A P" first="Pilar Pérez" last="Bre A">Pilar Pérez Bre A</name><name sortKey="Casas, Inmaculada" sort="Casas, Inmaculada" uniqKey="Casas I" first="Inmaculada" last="Casas">Inmaculada Casas</name><name sortKey="Castilla, Jesus" sort="Castilla, Jesus" uniqKey="Castilla J" first="Jesús" last="Castilla">Jesús Castilla</name><name sortKey="Cenoz, Manuel Garcia" sort="Cenoz, Manuel Garcia" uniqKey="Cenoz M" first="Manuel García" last="Cenoz">Manuel García Cenoz</name><name sortKey="De Mateo, Salvador" sort="De Mateo, Salvador" uniqKey="De Mateo S" first="Salvador" last="De Mateo">Salvador De Mateo</name><name sortKey="Galmes, Antonia" sort="Galmes, Antonia" uniqKey="Galmes A" first="Antonia" last="Galmés">Antonia Galmés</name><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name><name sortKey="Martinez, Ana" sort="Martinez, Ana" uniqKey="Martinez A" first="Ana" last="Martinez">Ana Martinez</name><name sortKey="Perucha, Milagros" sort="Perucha, Milagros" uniqKey="Perucha M" first="Milagros" last="Perucha">Milagros Perucha</name><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name><name sortKey="Qui Ones, Carmen" sort="Qui Ones, Carmen" uniqKey="Qui Ones C" first="Carmen" last="Qui Ones">Carmen Qui Ones</name><name sortKey="Ramos, Julian M" sort="Ramos, Julian M" uniqKey="Ramos J" first="Julián M" last="Ramos">Julián M. Ramos</name><name sortKey="Rodriguez, Carolina" sort="Rodriguez, Carolina" uniqKey="Rodriguez C" first="Carolina" last="Rodriguez">Carolina Rodriguez</name><name sortKey="Serrano, Maria C" sort="Serrano, Maria C" uniqKey="Serrano M" first="Maria C" last="Serrano">Maria C. Serrano</name><name sortKey="Torner, Nuria" sort="Torner, Nuria" uniqKey="Torner N" first="Nuria" last="Torner">Nuria Torner</name><name sortKey="Vanrell, Juana M" sort="Vanrell, Juana M" uniqKey="Vanrell J" first="Juana M" last="Vanrell">Juana M. Vanrell</name><name sortKey="Vega, Tomas" sort="Vega, Tomas" uniqKey="Vega T" first="Tomas" last="Vega">Tomas Vega</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Savulescu, Camelia" sort="Savulescu, Camelia" uniqKey="Savulescu C" first="Camelia" last="Savulescu">Camelia Savulescu</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000375 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000375 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22129083
|texte= Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22129083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |